252 related articles for article (PubMed ID: 37546802)
21. Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders.
Gurung R; Om D; Pun R; Hyun S; Shin D
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568727
[TBL] [Abstract][Full Text] [Related]
22. Structural studies of WDR5 in complex with MBD3C WIN motif reveal a unique binding mode.
Yang Y; Xu L; Zhang S; Yao L; Ding Y; Li W; Chen X
J Biol Chem; 2024 Jun; ():107468. PubMed ID: 38876301
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
[TBL] [Abstract][Full Text] [Related]
24. Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R; Secker-Grob KA; Keppeler H; Korkmaz F; Schairer R; Erkner E; Schneidawind D; Lengerke C; Hentrich T; Schulze-Hentrich JM; Schneidawind C
Neoplasia; 2023 Jul; 41():100902. PubMed ID: 37148657
[TBL] [Abstract][Full Text] [Related]
25. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.
Han QL; Zhang XL; Ren PX; Mei LH; Lin WH; Wang L; Cao Y; Li K; Bai F
Acta Pharmacol Sin; 2023 Apr; 44(4):877-887. PubMed ID: 36207403
[TBL] [Abstract][Full Text] [Related]
26. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
[TBL] [Abstract][Full Text] [Related]
27. WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think.
Weissmiller AM; Fesik SW; Tansey WP
J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202281
[TBL] [Abstract][Full Text] [Related]
28. Uncovering NOTCH1 as a Promising Target in the Treatment of
Fischer J; Erkner E; Fitzel R; Radszuweit P; Keppeler H; Korkmaz F; Roti G; Lengerke C; Schneidawind D; Schneidawind C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833915
[No Abstract] [Full Text] [Related]
29. Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia.
Xu X; Schneider B
Cell Oncol (Dordr); 2019 Apr; 42(2):117-130. PubMed ID: 30446944
[TBL] [Abstract][Full Text] [Related]
30. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
[TBL] [Abstract][Full Text] [Related]
31. The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.
Lu K; Tao H; Si X; Chen Q
Front Oncol; 2018; 8():502. PubMed ID: 30488017
[TBL] [Abstract][Full Text] [Related]
32. MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program.
Xu J; Li L; Xiong J; denDekker A; Ye A; Karatas H; Liu L; Wang H; Qin ZS; Wang S; Dou Y
Cell Discov; 2016; 2():16008. PubMed ID: 27462455
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
[TBL] [Abstract][Full Text] [Related]
34. JMJD1C-regulated lipid synthesis contributes to the maintenance of
Qi D; Wang J; Zhao Y; Yang Y; Wang Y; Wang H; Wang L; Wang Z; Xu X; Hu Z
Leuk Lymphoma; 2022 Sep; 63(9):2149-2160. PubMed ID: 35468015
[No Abstract] [Full Text] [Related]
35. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
[TBL] [Abstract][Full Text] [Related]
36. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
37. FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.
Zhu XN; Wei YS; Yang Q; Liu HR; Zhi Z; Zhu D; Xia L; Hong DL; Yu Y; Chen GQ
J Hematol Oncol; 2023 Feb; 16(1):9. PubMed ID: 36774506
[TBL] [Abstract][Full Text] [Related]
38. p53 inactivation unmasks histone methylation-independent WDR5 functions that drive self-renewal and differentiation of pluripotent stem cells.
Li Q; Huang Y; Xu J; Mao F; Zhou B; Sun L; Basinski BW; Aksu M; Liu J; Dou Y; Rao RC
Stem Cell Reports; 2021 Nov; 16(11):2642-2658. PubMed ID: 34715053
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
40. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]